Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Regenxbio Inc’s stock clocked out at $8.39, down -4.11% from its previous closing price of $8.75. In other words, the price has decreased by -$4.11 from its previous closing price. On the day, 1.18 million shares were traded. RGNX stock price reached its highest trading level at $8.99 during the session, while it also had its lowest trading level at $8.1899.
Ratios:
To gain a deeper understanding of RGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 2.93. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 12 ’25 when Mills Kenneth T. sold 20,602 shares for $7.91 per share. The transaction valued at 163,046 led to the insider holds 475,103 shares of the business.
KENNETH MILLS bought 20,602 shares of RGNX for $154,927 on May 12 ’25. On Dec 30 ’24, another insider, VITTAL VASISTA, who serves as the Officer of the company, bought 20,041 shares for $7.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 422761216 and an Enterprise Value of 286502368. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.70 while its Price-to-Book (P/B) ratio in mrq is 1.53. Its current Enterprise Value per Revenue stands at 1.828 whereas that against EBITDA is -2.027.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.08, which has changed by -0.24209577 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $15.36, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is -5.24%, while the 200-Day Moving Average is calculated to be -3.32%.
Shares Statistics:
It appears that RGNX traded 1.14M shares on average per day over the past three months and 1022880 shares per day over the past ten days. A total of 50.12M shares are outstanding, with a floating share count of 45.66M. Insiders hold about 9.39% of the company’s shares, while institutions hold 86.64% stake in the company. Shares short for RGNX as of 1749772800 were 5512274 with a Short Ratio of 4.84, compared to 1747267200 on 6303414. Therefore, it implies a Short% of Shares Outstanding of 5512274 and a Short% of Float of 13.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.08, with high estimates of $2.6 and low estimates of -$1.18.
Analysts are recommending an EPS of between $2.7 and -$3.36 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is -$1.52, with 7.0 analysts recommending between $0.99 and -$4.4.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $40.87M. It ranges from a high estimate of $142.89M to a low estimate of $20M. As of the current estimate, Regenxbio Inc’s year-ago sales were $22.3MFor the next quarter, 9 analysts are estimating revenue of $110.02M. There is a high estimate of $222M for the next quarter, whereas the lowest estimate is $21M.
A total of 11 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $425.21M, while the lowest revenue estimate was $150M, resulting in an average revenue estimate of $335.86M. In the same quarter a year ago, actual revenue was $83.33MBased on 11 analysts’ estimates, the company’s revenue will be $283.88M in the next fiscal year. The high estimate is $482.9M and the low estimate is $91.84M.
